Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Harvard Business School

Last Updated: December 6, 2021

DrugPatentWatch Database Preview

Patent: 7,550,143

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 7,550,143
Title:Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. Other embodiments concern tetramers comprising a first and second homodimer, which may be identical or different. The disclosed methods and compositions provide a facile and general way to obtain homodimers, homotetramers and heterotetramers of virtually any functionality and/or binding specificity.
Inventor(s): Chang; Chien Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), McBride; William J. (Boonton, NJ), Rossi; Edmund A. (Nutley, NJ)
Assignee: IBC Pharmaceuticals, Inc. (Morris Plains, NJ)
Application Number:11/389,358
Patent Claims:see list of patent claims

Details for Patent 7,550,143

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 1978-01-10 ⤷  Free Forever Trial 2025-04-06
Janssen Biotech, Inc. REOPRO abciximab Injection 103575 1994-12-22 ⤷  Free Forever Trial 2025-04-06
Swedish Orphan Biovitrum Ab (publ) SYNAGIS palivizumab For Injection 103770 1998-06-19 ⤷  Free Forever Trial 2025-04-06
Swedish Orphan Biovitrum Ab (publ) SYNAGIS palivizumab Injection 103770 2004-07-23 ⤷  Free Forever Trial 2025-04-06
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 1998-08-24 ⤷  Free Forever Trial 2025-04-06
Genentech, Inc. XOLAIR omalizumab For Injection 103976 2003-06-20 ⤷  Free Forever Trial 2025-04-06
Genentech, Inc. XOLAIR omalizumab Injection 103976 2018-09-28 ⤷  Free Forever Trial 2025-04-06
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.